Table 2.
Weight loss drugs in clinical development
| Agent | Company | Development stage | Indication | ClinicalTrials.gov ID/ref.a |
|---|---|---|---|---|
| GLP1/glucagon dual agonists | ||||
| Cotadutide (MEDI0382) | AstraZeneca | Phase II | T2D, NASH | |
| BI 456906 | Boehringer Ingelheim | Phase II | Obesity, T2D | NCT04153929 |
| Efinopegdutide (LAPSGLP/GCG) | Hanmi Pharmaceutical | Phase II | NASH | NCT03486392 |
| OXM | Eli Lilly | Phase I | T2D | See Related links |
| GIP/GLP1 dual agonists | ||||
| Tirzepatide | Eli Lilly | Phase III | Obesity, T2D | NCT04657003 |
| GIP/GLP peptide I | Eli Lilly | Phase I | T2D | See Related links |
| GIP/GLP peptide II | Eli Lilly | Phase I | T2D | See Related links |
| NN9709 | Novo Nordisk | Discontinued | Obesity, T2D | See Related links |
| GIP/GLP1/glucagon tri-agonists | ||||
| HM15211 (LAPSTriple Agonist) | Hanmi Pharmaceutical | Phase II | NASH | NCT04505436 |
| GGG tri-agonist | Eli Lilly | Phase I | T2D | See Related links |
| NN9423 | Novo Nordisk | Discontinued | Obesity, T2D | See Related links |
| GIPR agonists | ||||
| GIPR agonist long acting | Eli Lilly | Phase I | T2D | See Related links |
| ZP 6590 | Zealand Pharma | Preclinical | Obesity | See Related links |
| GLP1R agonists | ||||
| Efpeglenatide (LAPSExd4 Analog) | Hanmi Pharmaceutical | Phase III | T2D | |
| Rybelsus | Novo Nordisk | Phase III | Obesity | NCT03919929 |
| Danuglipron (PF-06882961) | Pfizer | Phase II | Obesity, T2D | |
| GLPR-NPA | Eli Lilly | Phase I | T2D | See Related links |
| PF-07081532 | Pfizer | Phase I | T2D | NCT04305587 |
| Glucagon analogue | ||||
| HM15136 (LAPSGlucagon Analog) | Hanmi Pharmaceutical | Phase I | Obesity | See Related links |
| Leptin sensitizers | ||||
| Withaferin A | Academic, non-commercial | Phase I | Obesity, T2D | 293 |
| Celastrol | Academic, non-commercial | Preclinical | Obesity, T2D | 294 |
| Leptin/amylin | Amylin Pharmaceuticals | Discontinued | Obesity, T2D | See Related links |
| Y2R agonists | ||||
| PYY analogue | Eli Lilly | Phase I | T2D | See Related links |
| NN9748 (NN9747) | Novo Nordisk | Phase I | Obesity, T2D | NCT03574584 |
| NNC0165-1875 + semaglutide | Novo Nordisk | Phase II | Obesity, T2D | NCT04969939 |
| Amylin/calcitonin dual agonists | ||||
| KBP-089 | Nordic Biosciences | Phase I | T2D | NCT03907202 |
| KBP-042 | Nordic Biosciences | Discontinued | T2D | NCT03230786 |
| Davalintide | Amylin Pharmaceuticals | Discontinued | Obesity, T2D | See Related links |
| Amylin analogues | ||||
| Cagrilintide | Novo Nordisk | Phase II | Obesity, T2D | |
| ZP 8396 | Zealand Pharma | Preclinical | Obesity | See Related links |
| Drugs targeting the ghrelin pathway | ||||
| CYT009-GhrQb | Cytos Biotechnology | Phase I | Obesity | See Related links |
| Nox-B11 | Noxxon Pharma | Preclinical | Obesity | See Related links |
| AZP-531 | Millendo Therapeutics SAS | Discontinued | Hyperphagia in patients with Prader–Willi syndrome | NCT03790865 |
| Mitochondrial uncoupler | ||||
| BAM15 | Continuum Biosciences | Preclinical | Obesity, NASH | See Related links |
| Other appetite suppressants | ||||
| GDF15 (LA-GFD15) | Novo Nordisk | Phase I | Obesity | See Related links |
| LY-3463251 (GDF15 agonist) | Lilly | Phase I | T2D, obesity | NCT03764774 |
| JNJ-9090/CIN-109 (GDF15 agonist) | Jansenn/CinFina Pharma | Phase I | Obesity | NA |
GDF15, growth differentiation factor 15; GIP, glucose-dependent insulinotropic polypeptide; GLP1, glucagon-like peptide 1; GLP1R, GLP1 receptor; NA, not applicable; NASH, nonalcoholic steatohepatitis; OXM, oxyntomodulin; PYY, peptide tyrosine tyrosine; T2D, type 2 diabetes; Y2R, neuropeptide Y receptor type 2. aSee Related links for further information.